| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.24 | 5e-07 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.2 | 3e-05 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.17 | 0.0007 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.098 | 0.002 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | -0.097 | 0.002 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.15 | 0.004 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.004 |